BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 36649877)

  • 1. JAK inhibitors and autoimmune rheumatic diseases.
    Benucci M; Bernardini P; Coccia C; De Luca R; Levani J; Economou A; Damiani A; Russo E; Amedei A; Guiducci S; Bartoloni E; Manfredi M; Grossi V; Infantino M; Perricone C
    Autoimmun Rev; 2023 Apr; 22(4):103276. PubMed ID: 36649877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
    Tanaka Y; Luo Y; O'Shea JJ; Nakayamada S
    Nat Rev Rheumatol; 2022 Mar; 18(3):133-145. PubMed ID: 34987201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
    Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK Inhibitors: Prospects in Connective Tissue Diseases.
    You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibitor: Introduction.
    Raychaudhuri SP; Raychaudhuri SK
    Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
    Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Jakinibs in systemic lupus erythematosus: progress and prospects.
    Mok CC
    Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
    Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
    Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK inhibition in the treatment of inflammatory rheumatic diseases.
    Šenolt L
    Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
    Jamilloux Y; El Jammal T; Vuitton L; Gerfaud-Valentin M; Kerever S; Sève P
    Autoimmun Rev; 2019 Nov; 18(11):102390. PubMed ID: 31520803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
    Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
    Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
    El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
    Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update.
    Chuprin J; McCormack L; Richmond JM; Rashighi M
    Expert Rev Clin Immunol; 2022 Mar; 18(3):263-272. PubMed ID: 35209781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects of targeting JAK/STAT signal transduction pathways for vasculitis.
    Huo RX; Yang YT; Yang Y; Huo XC; Meng DL; Huang RJ; Huang YJ; Lin JY; Zhu X; Wei CC; Huang XX
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):1864-1872. PubMed ID: 38497869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome.
    Charras A; Arvaniti P; Le Dantec C; Arleevskaya MI; Zachou K; Dalekos GN; Bordon A; Renaudineau Y
    Clin Rev Allergy Immunol; 2020 Apr; 58(2):182-193. PubMed ID: 31165348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
    Solimani F; Meier K; Ghoreschi K
    Front Immunol; 2019; 10():2847. PubMed ID: 31849996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.